[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subdural-hematoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subdural-hematoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,50,80,111,135,181,206,227],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100641148","non-thermal-plasma-to-reduce-recurrence-in-chronic-subdural-hematoma-100641148",false,"NCT07656818","Non-Thermal Plasma to Reduce Recurrence in Chronic Subdural Hematoma","Application of Non-Thermal Plasma in the Surgical Bed of Chronic Subdural Hematoma to Reduce the Post-Drainage Recurrence Rate: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults ≥ 18 years of age\n* Diagnosis of symptomatic chronic subdural hematoma (cSDH) requiring surgical drainage (burr hole drainage or craniotomy)\n* Ability to provide written informed consent (or consent from legal representative if patient is incapacitated)\n\nExclusion Criteria:\n\n* Pure acute or subacute subdural hematoma\n* Uncontrolled coagulopathy or bleeding disorder\n* History of intracranial aneurysm or prior cerebrovascular event with residual deficit\n* Presence of active intracranial metallic implants or electronic devices (e.g., programmable shunt, cardiac pacemaker, deep brain stimulator) in the head region\n* Pregnancy or lactation\n* Participation in another interventional clinical trial within 30 days prior to screening","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this randomized controlled trial is to evaluate whether the adjuvant application of non-thermal plasma (NTP) during standard surgical drainage of chronic subdural hematoma (cSDH) can reduce the recurrence rate at 6 months. The main questions it aims to answer are:\n\n* Does NTP application significantly lower the radiological and clinical recurrence rate of cSDH compared to surgery alone?\n* Is NTP safe when applied to the subdural space and surgical wound bed?\n* Does NTP improve functional outcomes and time to hematoma resolution?\n\nParticipants will be randomly assigned to one of two groups:\n\n* Experimental group (n = 20): Standard burr hole drainage or craniotomy plus intraoperative NTP application over the exposed dura mater, the residual membrane, soft tissue layers, and the skin incision.\n* Control group (n = 20): Standard surgical drainage alone (no NTP).\n\nFollow-up includes clinical assessments and computed tomography (CT) scans at 1 week, 3 months, and 6 months post-surgery. The primary outcome is recurrence (symptomatic reaccumulation requiring re-intervention or ≥50% volume increase on CT).",[26,27,28,29],"Chronic Subdural Hematoma","Subdural Hematoma","Recurrence","Postoperative Complications",[31,32,33,34,35,36],"Non-thermal plasma","Cold plasma","Chronic subdural hematoma","Neurosurgery","Recurrence prevention","Wound healing","RECRUITING","2026-06-16",{"date":40,"type":41},"2026-06-18","ACTUAL",{"date":43,"type":41},"2026-03-02",{"date":45,"type":20},"2027-04-30",{"name":47,"class":48},"Benjamín Gonzalo Rodríguez Méndez","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":49},"100494088","phase-3-the-use-of-tranexamic-acid-in-the-treatment-of-symptomatic-subdural-hematoma-100494088","NCT05713630","The Use of Tranexamic Acid in the Treatment of Symptomatic Subdural Hematoma","TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma","TRACE","Inclusion Criteria:\n\n* Patients aged 45 and older weighing between 45-150 kg diagnosed with symptomatic SDH will be included. SDH is defined as unilateral or bilateral crescentic collection of blood (hyper, iso, or hypodense, or mixed density) of greater than or equals to 8 mm in thickness along the cerebral convexity on CT of the head. Symptomatic SDH patients eligible for inclusion are those with SDH with one or more of the following symptoms attributable to the SDH: headache, gait disturbance, confusion or cognitive decline, limb weakness or numbness\u002Fparesthesia, speech or visual disturbance, drowsiness or impaired consciousness, seizures, impaired cognition, or memory loss at the time of assessment.\n\nExclusion Criteria:\n\n\\- Patients will be excluded for any of the following conditions:\n\n1. Asymptomatic for longer than 72 hours\n2. SDH less than 8 mm in maximal thickness\n3. Have an acutely deteriorating neurological status (e.g., brain herniation with pupillary dilation, aneurysm rupture, etc.) that is likely to be fatal within 6 hours or less due to a predominantly acute SDH\n4. Presence of brain contusion larger than 5 cubic centimeters or subarachnoid hemorrhage (SAH) thicker than 10 mm with Glasgow Coma Scale (GCS)\\\u003C 13\n5. Patients with primarily interhemispheric or tentorial SDH\n6. Hypersensitivity to TXA or any of the placebo ingredients\n7. Pregnancy\n8. Irregular menstrual bleeding with unidentified cause\n9. Known acquired colour vision disturbances\n10. Hematuria caused by renal parenchymal disease\n11. Acute and chronic renal insufficiency indicated by estimated Glomerular Filtration Rate (eGFR) ≤ 30 mL\u002Fmin\n12. Concomitant intake of birth control pill and\u002For hormonal replacement therapy, and anti-inhibitor coagulant concentrates (factor VIII inhibitor bypass activity (FEIBA), factor VII, activated factor IX)\n13. Consumption coagulopathy\u002Fdisseminated intravascular coagulation (DIC) in the last 7 days\n14. Not competent to take study medication properly and regularly or not having access to caregiver that is able to comply with study medication administration\n15. Mechanical heart valve\n16. Liver cirrhosis\n17. Recent venous and\u002For arterial thromboembolism within 6 months of study enrolment\n18. SDH caused by intracranial hypotension\n19. Known thrombophilia (e.g., antiphospholipid syndrome)\n20. Any active malignancy: metastatic cancer systemically or to the brain or a primary malignant brain tumour treated within the last 6 months\n21. Previous enrolment in this trial for a prior episode\n22. Time interval \\>3 days from the time of clinical assessment to eligibility assessment\n23. Patients weighing \\\u003C45 kg or \\>150 kg\n24. Patients received any amount of TXA upon admittance to hospital prior to enrolment","45 Years",{"count":60,"type":20},130,[62],"PHASE3","Subdural hematoma (SDH) is a common condition experienced after head injury. Blood collects on the surface of the brain, causing headaches which can progress to confusion, weakness, or even coma. While patients with SDH often receive surgery, not all patients require surgery right away to ease pressure on the brain. After surgery, there can be up to 30 percent chance of more bleeding and the need for more surgeries. Given this, a drug capable of lowering the chance of more bleeding and speeding the recovery of the patient is highly desirable. In this study, we will test a commonly used, cheap drug called Tranexamic Acid (TXA). While the body stops unwanted and sometimes dangerous bleeding naturally by forming blood clots, TXA stops these blood clots from breaking down, which helps to keep bleeding spots plugged. Our previous study showed that TXA helped speed up patients' recovery; but a larger number of patients is necessary to evaluate how well TXA works to reduce bleeding and improve patient-reported outcomes. In this study, regardless of the need for surgery, half of the patients will be randomly assigned to take TXA, while the other half will take a placebo, which is a look-alike substance that contains no active drug. We will measure multiple outcomes over time to determine if TXA is working and lowers healthcare and personal costs, while also taking blood and surgical samples, to better understand how this drug works in SDH patients.",[27],[66,67,68,69,70],"symptomatic subdural hematoma","tranexamic acid","TXA","clinical trial","neurosurgery","2026-05-26",{"date":73,"type":41},"2026-05-29",{"date":75,"type":20},"2026-05-20",{"date":77,"type":20},"2030-12-31",{"name":79,"class":48},"Unity Health Toronto",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":110},"100634570","mma-embolization-with-neocast-for-subacute-and-chronic-subdural-hematoma-100634570","NCT07541404","MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma","Pivotal Study of the Treatment of Symptomatic Subacute and Chronic Subdural Hematoma Via Middle Meningeal Artery Embolization With the NeoCastTM Embolic System (RADIANT)","RADIANT","Inclusion Criteria:\n\n* Participant whose age is ≥ 18 and ≤ 90 years;\n* Pre-morbid mRS ≤ 2;\n* Confirmed diagnosis of subacute or chronic subdural hematoma that measures ≥10 mm in greatest thickness;\n* Participant presents with one or more of the following corroborating neurological symptoms: headache; cognitive decline; speech difficulty; gait impairment or imbalance; focal neurological deficit; and\u002For seizure, within the last 30 days;\n* Participant is planned for middle meningeal artery embolization within ±7 days of surgical evacuation of hematoma via burr hole or craniotomy;\n* Participant or Legally Authorized Representative\u002FPerson Responsible for consenting on their behalf understands the nature of the procedure, consents to participation in the study and provides a signed informed consent form;\n* Participant (woman of child-bearing potential) with a current negative pregnancy test who has agreed to an appropriate method of contraception throughout the trial;\n* Participant is willing to return to the investigational site for follow-up visits.\n\nExclusion Criteria:\n\n* Diagnosed with acute SDH\n* Participant with prior embolization of either MMA\n* Participant with urgent or emergent (within 1 hour of assessment) subdural hematoma evacuation needed\n* Participant with bilateral SDH where both sides require surgery or contralateral SDH \\>5mm in greatest thickness\n* Participant identified with potentially dangerous anatomic variations leading to increased procedural risk, risk of incomplete embolization, or unsafe access for MMA embolization (i.e., MMA originating from ophthalmic artery)\n* Participant who presents with a meningioma ≥1 cm or \\\u003C 1 cm with mass effect\n* Subjects with conditions placing them at high-risk for ischemic stroke who cannot be taken off anticoagulants for at least 7 days post-surgery\n* Participant currently undergoing radiation therapy for carcinoma or sarcomas of the head or neck region\n* SDH developed due to underlying condition or structure pathology (e.g., dural AV fistula, AVM, tumor, arachnoid cyst, ventriculoperitoneal shunt, spontaneous intracranial hypotension or previous craniotomy)\n* Presumed microbial superinfection\n* Participant who is breastfeeding\n* Participant with life expectancy of \\\u003C1 year\n* Participants with acute renal impairment that the investigator assesses could be at risk for contrast induced nephropathy\n* Participant with a life-threatening allergy to radiographic contrast (unless treatment for allergy is tolerated or can be managed medically)\n* Participant is allergic to any of the materials used in the NeoCast device or the Onyx LES commercial embolic device\n* Participant who is currently participating or planning to participate within 6 months in another clinical research study","90 Years",{"count":90,"type":20},360,[23],"The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the NeoCast Embolic System for treatment of symptomatic subacute or chronic subdural hematoma (SDH) adjunctive to surgery.",[27],[95,96,97,98,99],"Hematoma","Chronic subdural hematoma (cSDH)","Subacute subdural hematoma","Subdural hematoma (SDH)","Middle Meningeal Artery (MMA) Embolization","NOT_YET_RECRUITING","2026-05-18",{"date":75,"type":41},{"date":104,"type":20},"2026-07",{"date":106,"type":20},"2028-04",{"name":108,"class":109},"Arsenal Medical, Inc.","INDUSTRY",2,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100612783","study-on-histoacryl-used-for-embolization-of-middle-meningeal-artery-mma-in-chronic-subdural-hematoma-csdh-harmony-100612783","NCT07258069","Study On Histoacryl Used For Embolization Of Middle Meningeal Artery (MMA) In Chronic Subdural Hematoma (CSDH) (HARMONY)","Observational, Prospective, Multicenter Study On Histoacryl Used For Embolization Of Middle Meningeal Artery (MMA) In Chronic Subdural Hematoma (CSDH) (HARMONY)","HARMONY","Inclusion Criteria:\n\n* 18 years old or older\n* Confirmed diagnosis of chronic subdural hematoma (CSDH) or recurrent subdural hematoma (SDH)\n* Completed documented informed consent\n* Willingness and presumed capability to participate in follow-up visits for up to 6 months (180±30 days)\n\nExclusion Criteria:\n\n* Extensive cerebral infarction, brain tumor, or space-occupying lesion requiring treatment\n* Need craniotomy\n* Any sign of anatomical variations that could make MMA embolization unsafe (e.g., prominent MMA-opthalmic artery anastomoses)\n* Coagulation dysfunction with INR\\>1.8 and\u002For platelet count \\\u003C80x109 \u002FL\n* Allergic reactions to essential medicines to do angiography\n* Women who are pregnant, lactating, or who are of childbearing age and plan on becoming pregnant during the study\n* Participation in another clinical trial",{"count":120,"type":20},178,"OBSERVATIONAL","The aim of the study is to proof the effectiveness of Histoacryl® on preventing recurrence or progression of subdural hematoma after embolization of the middle meningeal artery.",[27,124],"Subdural Hematoma, Chronic","2026-04-15",{"date":127,"type":41},"2026-04-17",{"date":129,"type":41},"2026-04-10",{"date":131,"type":20},"2027-08",{"name":133,"class":109},"Aesculap AG",7,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":145,"conditions":146,"keywords":169,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100571728","neurosurgical-outcome-network-100571728","NCT06724029","Neurosurgical Outcome Network","Neurosurgical Outcome Network Per la Predizione Dell'Outcome in Neurochirurgia","NEON","Inclusion Criteria:\n\n* Neuro-oncological pathology: supratentorial and subtentorial tumors, intra and extra axial tumors excluding the skull base (anterior, middle and posterior fossa; sellar and parasellar region)\n* Basicranial pathology: tumors originating from the anterior cranial fossa, middle cranial fossa and posterior cranial fossa, sellar region with or without supratentorial\u002Fparasellar development.\n* Vascular pathology: aneurysms, AVMs, cavernomas, other pathologies (Moyamoya disease, dural fistulas, nontraumatic hematomas)\n* Traumatic pathology: diffuse damage (nonvisible diffuse damage, diffuse damage, diffuse damage with edema, diffuse damage with shift) and focal damage (acute\u002Fsubacute\u002Fchronic subdural hematoma, extradural hematoma, subarachnoid hemorrhage, intraparenchymal hematoma, fractures); hydrocephalus. The inclusion criterion for chronic subdural hematoma is recent bleeding for TBI with CT finding of chronic subdural hematoma candidate for evacuation surgery.\n* Spinal pathology: degenerative cervical (anterior\u002Fposterior), myelopathic, and trauma pathology; instrumented, uninstrumented thoracolumbar pathology (disc pathology, canal pathology), and trauma pathology; oncologic spinal pathology.\n* Functional pathology: Parkinson's disease, spasticity, trigeminal neuralgia, craniofacial pain\u002Falgia, neuropathic pain, tremor, dystonias, obsessive compulsive disorder, drug-resistant epilepsies, depression. Normotensive hydrocephalus.\n* Peripheral nervous system pathology: peripheral nerve compression syndromes, peripheral nerve and plexus tumors, brachial plexus and peripheral nerve trauma (contusion and section)\n* Malformative pathology: Chiari malformation type 1 and craniostenoses including both those framed in malformative syndromes and those not framed in malformative syndromes (monosutural craniostenoses: trigonocephaly, plagiocephaly, scaphocephaly; multisutural craniostenoses). Malformative hydrocephalus.\n* For cognitive and psychological assessment: age 18 years or older; adequate understanding of Italian language; diagnosis of glioma, meningioma, vascular pathology, spinal pathology\n\nExclusion Criteria:\n\n* For cognitive and psychological assessment: patients with psychiatric diseases in history and\u002For taking psychotropic drugs; presence of overt cognitive decline (not due to the injury) in history; patients younger than 18 years old.",{"count":144,"type":20},4500,"The evaluation of neurosurgical outcomes varies from center to center, and the predictive factors that determine these outcomes are not fully known or shared. This study aims to assess outcomes and their predictors using measures agreed upon by the participating centers. Standardizing the evaluation of outcomes and predictors improves the quality of research, allows for data comparison, and facilitates a \"common language\" in routine clinical practice. Most importantly, it influences therapeutic decisions in various neurosurgical conditions. Clinically, the identified predictors can also be used during preoperative assessments to provide more precise guidance to patients undergoing surgery.",[147,148,149,150,151,152,27,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168],"Aneurysms","Arteriovenous Malformations","Cavernomas","Skull Base Tumors","Moyamoya Disease","Dural Fistulas","Extradural Hematoma","Subarachnoid Hemorrhage","Hydrocephalus","Parkinson&Amp;#39;s Disease","Spasticity","Trigeminal Neuralgia","Craniofacial Pain","Neuropathic Pain","Tremor","Dystonias","Obsessive-compulsive Disorder","Drug-resistant Epilepsy","Depression","Normal Pressure Hydrocephalus","Tumors of Peripheral Nerves","Chiari Malformation Type 1",[170],"Neurosurgery Outcome Artificial Intelligence predictors","2026-03-25",{"date":173,"type":41},"2026-03-30",{"date":175,"type":41},"2022-12-05",{"date":177,"type":20},"2027-06",{"name":179,"class":48},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",27,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":49},"100433427","embolization-of-middle-meningeal-artery-for-subdural-hematoma-in-canada-emma-can-100433427","NCT04923984","Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)","Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada -EMMA-Can","EMMA-Can","Inclusion Criteria:\n\n\\- All patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic.\n\nExclusion Criteria:\n\n* If informed consent cannot be obtained from the patient or their substitute decision maker.\n* Known allergy to liquid embolic agent",{"count":190,"type":20},1000,[23],"EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH.\n\nHypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.",[27],[195,196,26],"Embolization","Middle Meningeal Artery","2026-02-02",{"date":199,"type":41},"2026-02-03",{"date":201,"type":41},"2021-05-01",{"date":203,"type":20},"2029-12-31",{"name":205,"class":48},"University of Manitoba",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":21,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":49},"100603998","scalp-block-versus-general-anesthesia-in-patients-undergoing-evacuation-of-subdural-hematoma-via-burr-hole-100603998","NCT07143799","Scalp Block Versus General Anesthesia in Patients Undergoing Evacuation of Subdural Hematoma Via Burr Hole","Inclusion Criteria\n\n* Age from 18 to 75 years old.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status II-III.\n* Patients with subdural hematoma undergoing burr-hole evacuation\n\nExclusion Criteria:\n\n* Patients with a history of known sensitivity to study drugs.\n* Glasgow Coma Scale (GCS) \\\u003C8\n* Impaired coagulation profile.\n* Any degree of heart block.\n* Infection at site of injection","75 Years",{"count":214,"type":20},80,[23],"this study amis to compare between Scalp block versus general anesthesia in patients undergoing evacuation of subdural hematoma via burr hole.",[27],"2025-08-22",{"date":220,"type":41},"2025-08-27",{"date":222,"type":41},"2025-08-11",{"date":224,"type":20},"2026-03-20",{"name":226,"class":48},"Sohag University",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":21,"phases":237,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":49},"100489191","affect-study-for-patients-with-intraventricular-hemorrhage-subarachnoid-hemorrhage-subdural-hematoma-and-ventriculitis-100489191","NCT05649904","AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis","Use of Active Fluid Exchange to Therapeutically Treat Intracranial Bleeding and Infection","AFFECT","Inclusion Criteria:\n\n1. Age ≥18 years of age\n2. Need of drainage for one of the following underlying conditions: Intraventricular hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage, chronic subdural hematoma and ventriculitis\n3. Indication for active treatment evaluated by treating physician for underlying conditions; Intraventricular hemorrhage, subarachnoid hemorrhage, chronic subdural hematoma and ventriculitis\n4. Signed informed consent obtained by subject or Legally Authorized Representative\n\nExclusion Criteria:\n\n1. Subject has fixed and dilated pupils\n2. Pregnant women\n3. Presence of Moyamoya\n4. History or presence of clotting disorder.\n5. Platelet count less than 100,000, INR greater than 1.4",{"count":236,"type":20},240,[23],"The goal of this clinical trial is to evaluate efficacy and safety of evacuation of cerebrospinal fluid, blood, and harmful bacteria from the intraventricular, subdural and subarachnoid spaces by Active Controlled Irrigation and Drainage (IRRAflow) compared to Passive External Ventricular Drainage (EVD).\n\nSubjects with intraventricular hemorrhage, subarachnoid hemorrhage, subdural bleeding, and ventriculitis will be randomized to receive the IRRAflow device or EVD device and followed for one month post-procedure to compare outcomes between the subject groups.",[240,154,27,241],"Intraventricular Hemorrhage","Ventriculitis","2025-03-26",{"date":244,"type":41},"2025-04-01",{"date":246,"type":41},"2023-02-07",{"date":248,"type":20},"2026-01",{"name":250,"class":48},"Ohio State University"]